Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of afamelanotide implants in polymorphic light eruption
2009-010843-15Phase 3Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- May 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in polymorphic light eruption (PMLE) comparing Afamelanotide arm with Placebo arm (2 arms). Primary endpoint: Primary objective. Started May 2009; status: completed.
02
Drugs
Afamelanotide
03
Conditions
polymorphic light eruption (PMLE)
Beyond the preview
Go deeper on 2009-010843-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010843-15.